These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 28411279)
1. Characterization and Interspecies Scaling of rhTNF- Chen X; DuBois DC; Almon RR; Jusko WJ Drug Metab Dispos; 2017 Jul; 45(7):798-806. PubMed ID: 28411279 [TBL] [Abstract][Full Text] [Related]
2. Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor- Chen X; DuBois DC; Almon RR; Jusko WJ Drug Metab Dispos; 2017 Jul; 45(7):790-797. PubMed ID: 28411280 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881 [TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Libutti SK; Paciotti GF; Byrnes AA; Alexander HR; Gannon WE; Walker M; Seidel GD; Yuldasheva N; Tamarkin L Clin Cancer Res; 2010 Dec; 16(24):6139-49. PubMed ID: 20876255 [TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of onercept in healthy subjects. Glatt S; Fuseau E; Buraglio M; Nguyen QT Clin Pharmacokinet; 2005; 44(12):1295-304. PubMed ID: 16372827 [TBL] [Abstract][Full Text] [Related]
7. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy. Ferraiolo BL; McCabe J; Hollenbach S; Hultgren B; Pitti R; Wilking H Drug Metab Dispos; 1989; 17(4):369-72. PubMed ID: 2571474 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic model of human insulin following different routes of administration. Potocka E; Baughman RA; Derendorf H J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337 [TBL] [Abstract][Full Text] [Related]
10. Tissue distribution of recombinant human tumor necrosis factor alpha derivative in mice. Chai BX; Tang ZM; Liu XW; Tu M Zhongguo Yao Li Xue Bao; 1999 Apr; 20(4):371-4. PubMed ID: 10452128 [TBL] [Abstract][Full Text] [Related]
11. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. Postma NS; Crommelin DJ; Eling WM; Zuidema J J Pharmacol Exp Ther; 1999 Jan; 288(1):114-20. PubMed ID: 9862761 [TBL] [Abstract][Full Text] [Related]
12. Modification of TNF-alpha pharmacokinetics in SA-1 tumor-bearing mice. Kus B; Sersa G; Novaković S; Urbancic J; Stalc A Int J Cancer; 1993 Aug; 55(1):110-4. PubMed ID: 8344743 [TBL] [Abstract][Full Text] [Related]
13. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. Zimmerman RJ; Marafino BJ; Chan A; Landre P; Winkelhake JL J Immunol; 1989 Feb; 142(4):1405-9. PubMed ID: 2915120 [TBL] [Abstract][Full Text] [Related]
14. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Glassman PM; Balthasar JP J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311 [TBL] [Abstract][Full Text] [Related]
15. Characterization of receptors for recombinant human tumor necrosis factor-alpha from human placental membranes. Aiyer RA; Aggarwal BB Lymphokine Res; 1990; 9(3):333-44. PubMed ID: 2169011 [TBL] [Abstract][Full Text] [Related]
16. IL-4 and TNF-alpha-mediated proliferation of the human megakaryocytic line M-O7E is regulated by induced autocrine production of GM-CSF. Wadhwa M; Dilger P; Meager A; Walker B; Gaines-Das R; Thorpe R Cytokine; 1996 Dec; 8(12):900-9. PubMed ID: 9050748 [TBL] [Abstract][Full Text] [Related]
17. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513 [TBL] [Abstract][Full Text] [Related]
18. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. Greischel A; Zahn G J Pharmacol Exp Ther; 1989 Oct; 251(1):358-61. PubMed ID: 2795465 [TBL] [Abstract][Full Text] [Related]
20. The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. Brouckaert P; Everaerdt B; Fiers W Eur J Immunol; 1992 Apr; 22(4):981-6. PubMed ID: 1532365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]